Page 14 - Michael Erman News Today

Novavax said on Thursday it has agreed to pay back international vaccine group Gavi at least $475 million in cash or vaccines by the end of 2028, settling a dispute over canceled orders that had created financial uncertainty for the U.S. maker of COVID-19 shots. Gavi, an alliance that co-finances vaccine purchases with low-income countries, paid Novavax $700 million over 2021 and 2022 for up to 350 million doses of its COVID vaccine. Novavax, which launched its vaccine after several competitor...

Moderna fell as much as 7% on Friday after Wall Street analysts raised concerns over faster declines in the efficacy of its experimental respiratory syncytial virus vaccine when compared with rival...

(This Feb. 9 story has been corrected to say efficacy of Pfizers shot fell from 89% to 79% in the mid-season two, not to 49% from 67% in 17 months, in ...

By Deena Beasley (Reuters) -Gilead Sciences on Tuesday said fourth-quarter revenue dipped 4% on lower sales of HIV drugs and its infused COVID-19 treatment ...

Drugmaker Bristol Myers Squibb on Friday posted better-than-expected results for the fourth quarter as sales of its new anemia drug Reblozyl and its already off patent blood cancer drug Revlimid...

(Reuters) -Merck & Co reported better-than-expected fourth-quarter results on Thursday on strong sales of its cancer immunotherapy Keytruda, now the world's biggest selling prescription medicine. Keytruda sales rose 21% to $6.6 billion as the company was able to increase use of the drug in earlier stage cancers, topping analyst forecasts of $6.5 billion. For the full year, Keytruda generated $25 billion, surpassing sales of AbbVie's blockbuster arthritis drug Humira at its peak.

Pfizer on Tuesday reported a surprise quarterly profit, as COVID products demand was better than the companys expectations and lower research costs. The U.S. drugmaker earned 10 cents...

(Reuters) -Pfizer reported a surprise quarterly profit on Tuesday, helped by cost-cutting measures and fewer returns of its COVID treatment Paxlovid by the U.S. government than it had expected, but revenue fell short of Wall Street estimates. Investors fled Pfizer last year as pandemic worries declined and billions of dollars in COVID-19 vaccine and treatment sales disappeared. Overall revenue in the quarter was $14.25 billion, shy of Wall Street estimates of $14.42 billion.

Pharmaceutical companies are due to receive by Thursday the U.S. governments opening proposal for discounts it is seeking on 10 high-cost medicines, an important step in the Medicare health programs...

Pharmaceutical companies are due to receive by Thursday the U.S. governments opening proposal for what are expected to be significant discounts on 10 of its high-cost medicines, an important step in...